English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Arbekacin, an aminoglycoside antibiotic, has antibacterial activity against both Gram-positive and Gram-negative bacteria and is stable in the presence of aminoglycoside-inactivating enzymes produced by methicillin-resistant Staphylococcus aureus (MRSA). In this report, the antibacterial activity of arbekacin was compared with that of vancomycin, a glycopeptide antibiotic that also has potent antibacterial activity against MRSA. Arbekacin showed concentration-dependent bactericidal activity against MRSA strain 1936 (0.5-2 x MIC), but vancomycin showed only slight bactericidal activity, even at high concentrations of 19 x MIC. Arbekacin showed a longer post-antibiotic effect (2.3-3.8 h) than vancomycin (0-1.3 h) against MRSA strain 1936. Arbekacin induced marked morphological changes at 0.5 x MIC and the changes remained for 2 h after removal of the agent. When exposed to 0.5 x MIC of vancomycin, no notable morphological change was observed in the treated cells. Since arbekacin has broad-spectrum activity, these findings suggest that it may be a useful agent against MRSA infection, especially for polymicrobial MRSA infection with Gram-negative bacilli, such as Pseudomonas aeruginosa.

the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy

Comparative studies of the bactericidal, morphological and post- antibiotic effects of arbekacin and vancomycin against methicillin- resistant Staphylococcus aureus